We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

204 hedge funds and large institutions have $3.33B invested in Xenon Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 86 increasing their positions, 51 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

142% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 19

69% more repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 51

59% more capital invested

Capital invested by funds: $2.1B → $3.33B (+$1.23B)

56% more funds holding in top 10

Funds holding in top 10: 9 → 14 (+5)

13% more funds holding

Funds holding: 180 → 204 (+24)

2.19% more ownership

Funds ownership: 95.63% → 97.83% (+2.2%)

4% less call options, than puts

Call options by funds: $39M | Put options by funds: $40.6M

Holders
204
Holders Change
+24
Holders Change %
+13.33%
% of All Funds
2.97%
Holding in Top 10
14
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+55.56%
% of All Funds
0.2%
New
46
Increased
86
Reduced
51
Closed
19
Calls
$39M
Puts
$40.6M
Net Calls
-$1.6M
Net Calls Change
+$6.69M

Top Buyers

1
Wellington Management Group
Wellington Management Group
Massachusetts
+$86M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$49.6M
3
BlackRock
BlackRock
New York
+$38M
4
FLAM
First Light Asset Management
Minnesota
+$36.9M
5
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$31.5M

Top Sellers

1
BI
BVF Inc
California
-$33.1M
2
NIP
Nicholas Investment Partners
California
-$27.1M
3
Marshall Wace
Marshall Wace
United Kingdom
-$22.1M
4
SC
Samlyn Capital
New York
-$18.7M
5
B
Braidwell
Connecticut
-$16.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
TCM
26
TimesSquare Capital Management
New York
$36.6M +$7.19M +203,379 +34%
Invesco
27
Invesco
Georgia
$33.2M +$121K +3,415 +0.5%
Lord, Abbett & Co
28
Lord, Abbett & Co
New Jersey
$33.1M -$15.2M -431,196 -38%
Loomis, Sayles & Company
29
Loomis, Sayles & Company
Massachusetts
$32.6M -$792K -22,421 -3%
FTM
30
First Turn Management
California
$31.3M +$24M +680,389 New
BC
31
Boxer Capital
California
$27.6M – – –
GPP
32
Great Point Partners
Connecticut
$27.6M +$3.53M +99,999 +20%
Jennison Associates
33
Jennison Associates
New York
$26.1M +$12.5M +352,573 +165%
Fiera Capital (Canada)
34
Fiera Capital (Canada)
Quebec, Canada
$25.5M -$266K -7,516 -1%
O
35
OrbiMed
New York
$25.3M -$14.4M -408,793 -43%
CS
36
Candriam SCA
Luxembourg
$24.5M -$1.38M -39,000 -7%
AAA
37
Affinity Asset Advisors
New York
$21.2M +$5.64M +159,562 +53%
Morgan Stanley
38
Morgan Stanley
New York
$20.7M +$7.32M +207,149 +85%
SC
39
Samlyn Capital
New York
$19.4M -$18.7M -530,600 -56%
Dimensional Fund Advisors
40
Dimensional Fund Advisors
Texas
$18.5M -$864K -24,457 -6%
Goldman Sachs
41
Goldman Sachs
New York
$17.3M +$4.27M +120,934 +47%
Federated Hermes
42
Federated Hermes
Pennsylvania
$16M +$12.2M +346,596 New
Two Sigma Investments
43
Two Sigma Investments
New York
$15.7M +$9.16M +259,382 +322%
Vanguard Group
44
Vanguard Group
Pennsylvania
$14.9M +$2M +56,669 +21%
GIM
45
Granahan Investment Management
Massachusetts
$13.9M +$2.34M +66,291 +28%
PHP
46
Parkman Healthcare Partners
Connecticut
$13.6M +$2.76M +78,144 +36%
Franklin Resources
47
Franklin Resources
California
$13.5M +$4.28M +121,213 +70%
ACM
48
Altium Capital Management
New York
$13.4M +$2.21M +62,535 +27%
DCM
49
DAFNA Capital Management
California
$12.7M -$134K -3,799 -1%
BCM
50
Boone Capital Management
Georgia
$11.8M +$9.02M +255,432 New
1
2
3 4 5

XENE Hedge Fund Activity: Q4 2023 in Review

204 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2023, worth a combined $3.33B — up 59% from $2.1B a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new XENE positions and 19 closed out — a net gain of 27 holders — while 86 added to existing stakes and 51 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $86M. The largest seller was BVF Inc, cutting an estimated $33.1M.

  • 204 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2023, up from 180 in Q3 2023.
  • Funds reported $3.33B of Xenon Pharmaceuticals stock for Q4 2023, up 59% quarter-over-quarter.
  • 46 funds opened new Xenon Pharmaceuticals positions in Q4 2023 and 19 closed out, a net change of +27 holders.
  • The largest Xenon Pharmaceuticals buyer in Q4 2023 was Wellington Management Group, an estimated $86M added.
  • The largest Xenon Pharmaceuticals seller in Q4 2023 was BVF Inc, an estimated $33.1M sold.

Based on aggregated 13F filings for Q4 2023.